4243722
Download
1 / 11

~ftpb neurodegenerative disease companion - PowerPoint PPT Presentation


  • 109 Views
  • Uploaded on

Alzheimer's disease.  Section of neocortex stained with polyclonal antibody against βA4 peptide showing amyloid deposits in plaques in brain substance (arrow A) and in blood vessel walls (arrow B).

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about '~ftpb neurodegenerative disease companion' - lok


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
4243722

Alzheimer's disease. Section of neocortex stained with polyclonal antibody against βA4 peptide showing amyloid deposits in plaques in brain substance (arrow A) and in blood vessel walls (arrow B).


4243722

Fronto-temporal dementia. Lateral view of formalin-fixed brain from a patient who died of Pick's disease, showing gyral atrophy of frontal and parietal lobes and a more severe degree of atrophy affecting the anterior half of the temporal lobe (arrow). High power (× 200) of hippocampal pyramidal layer, prepared with monoclonal anti-tau antibody. Many neuronal cell bodies contain sharply circumscribed, spherical cytoplasmic inclusion bodies (Pick bodies).


4243722

Parkinson's disease. High power (× 400) of substantianigra of a patient with Parkinson's disease to show classical Lewy body (haematoxylin and eosin)


4243722

Mechanisms of drug action in Parkinson's disease. (1) Decarboxylase inhibitors (carbidopa and benserazide) decrease side-effects by reducing peripheral conversion of levodopa to dopamine by aromatic amino acid decarboxylase (AAAD). (2) Active transport of levodopa into the brain may be inhibited by competition from dietary amino acids after a high-protein meal. (3) In the nigrostriatal neurons, levodopa is converted into dopamine. (4) Amantadine enhances the release of dopamine at the nerve terminal. (5) Dopamine agonists act directly on striatal receptors. (6) The monoamine oxidase type B (MAO-B) inhibitor selegiline increases the availability of neuronal dopamine by reducing its metabolism outside the neuron. (7) The catechol-O-methyl-transferase (COMT) inhibitor entacapone prolongs the availability of dopamine by inhibiting the metabolism of dopamine and levodopa outside the neuron.


4243722


ad